Physiomics PLC - London-based mathematical modelling company that supports oncology drug development - Says it has been awarded a further contract by its existing client, Numab Therapeutics. Numab Therapeutics is a Switzerland-based biotechnology firm. The project involves pharmacokinetic-pharmacodynamic modelling in support of one of Numab’s clinical programs and follows on from earlier work conducted by Physiomics on the same asset. The project will span two years of the clinical program.

Chief Executive Jim Millen says: ‘We are delighted that we have a further opportunity to support Numab with its exciting clinical pipeline and look forward to working once again with their talented team.’

Current stock price: 0.95 pence, down 2.4% on Tuesday

12-month change: down 64%

Copyright 2023 Alliance News Ltd. All Rights Reserved.